Sobi's Revenues Decline 3% In Second Quarter, Signs Of Return To Normality In June
Kineret Shows Promise In COVID-19 Related Cytokine Storm Syndrome
Swedish Orphan Biovitrum’s financial performance in the second quarter was held back by COVID-19 related events, but it has left its financial guidance unchanged for 2020.
You may also be interested in...
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.